Eisai and Biogen Report Long-Term Benefits of LEQEMBI in Early Alzheimer's Disease

Eisai and Biogen have announced new findings on the long-term benefits of LEQEMBI in early Alzheimer's disease. The treatment has the potential to delay disease progression by up to 8.3 years in patients with low amyloid levels who began therapy at an early stage. New safety and efficacy data were also presented for the subcutaneous formulation of LEQEMBI, which was approved in the US and Japan in 2025.